Basic Search  |  Summaries  |  Advanced SearchPenalty: £22,000,000
Year: 2016
Date: 12 February, 2016
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: GlaxoSmithKline plc was fined £37.6 million in a decision by the CMA that the company made agreements with Generics (UK) and Alpharma where GSK would pay the two companies to delay entering the UK market with a generic version of the drug paroxetine (allowing GSKs branded version Seroxat to dominate the market at a higher price) in breach of competition law. In 2021 the Competition Appeal Tribunal reduced the fine to £22 million.
Action Type: agency action
Agency: Competition and Markets Authority
HQ Country of Parent: United Kingdom
Ownership Structure of Parent: publicly traded
Major Industry of Parent: pharmaceuticals
Specific Industry of Parent: pharmaceuticals
Source of Data: (click here)